Business
Enveric Biosciences Appoints New Independent Directors
-- Experienced Leaders Michael Webb, Bevin O’Neil and Frank Pasqualone Join Enveric’s Board of Directors -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric
About this update from Enveric Biosciences, Inc.
[{"type":"text","content":"\n-- Experienced Leaders Michael Webb, Bevin O’Neil and Frank Pasqualone Join Enveric’s Board of Directors --\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nEnveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors.\n\n“We are delighted to welcome Michael, Bevin and Frank to Enveric’s Board at this exciting inflection point in our Company’s history,” said Dr. Joseph Tucker, PhD, Enveric’s Chief Executive Officer. “Collectively, Michael’s proven track record in healthcare and life sciences, Bevin’s deep expertise in business operations and fundraising experience, and Frank’s global market expertise at Theravance and Bristol-Myers Squibb, will be invaluable to Enveric as we continue to advance our drug candidates towards the clinic. Their experience and seasoned leadership will further strengthen our platform as we look to advance our drug candidates.”\n\nMichael D. Webb\n\nMr. Webb has more than 25 years of experience in healthcare and life sciences. He specializes in early-stage companies focused on targeted therapeutics and molecular diagnostics. Currently, he is the President and CEO of CXL Ophthalmics. He has held Executive Chairman, Chairman, and CEO roles for numerous biotechnology companies, including venture-backed and NASDAQ-listed entities, as well as was previously the Chairman of MassBio, a biotechnology industry trade organization serving one of the top life sciences clusters in the world.\n\nBevin O’ Neil\n\nMs. O'Neil currently serves as the Chief Strategy Officer of ECRI, a nonprofit organization with 500 employees focused on advancing evidence-based, effective healthcare globally. Ms. O’Neil has over two decades of private equity, fundraising and operating experience, and has sat on several boards and audit committees of companies ranging from small entrepreneurial start-ups to global multi-billion dollar corporate enterprises.\n\nFrank Pasqualone\n\nMr. Pasqualone was most recently the Chief Business Officer of Therava...